Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR19TIF in r/r B-ALL
NCT07008885Phase 2
Key facts
- Status
- Recruiting
- Start
- Jun 2025
- Primary completion
- May 2026
- Countries
- 1
- Sponsor
- Chinese PLA General Hospital
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Drugs
- CAR19TIF
- Conditions
- B cell acute lymphoblastic leukemia (B-ALL)
01
Overview
Phase 2, open-label trial of CAR19TIF in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence of Adverse Events at 12 months, Incidence of Dose-Limiting Toxicities at 28 days and 4 more. Started Jun 2025; status: recruiting.
02
Design
- Study design
- Non-randomizedOpen-label
03
Endpoints
Primary
Incidence of Adverse Events
Incidence of Dose-Limiting Toxicities
Recommended Phase 2 Dose
Objective Response Rate
Overall Survival
Secondary
Level of CAR-positive T cells circulating in blood
Level of CD19+ cells in peripheral blood
Beyond the preview
Go deeper on NCT07008885.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008885.